Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Link opens in a new tab
Search content at University of Birmingham
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Aspirin as adjunctive treatment for giant cell arteritis
Susan P. Mollan
*
, Noor Sharrack
, Mike A. Burdon
,
Alastair K. Denniston
*
Corresponding author for this work
Immunology and Immunotherapy
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Aspirin as adjunctive treatment for giant cell arteritis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Aspirin
100%
Adjunctive Therapy
100%
Giant Cell Arteritis
100%
Low-dose Aspirin
57%
Ovid
57%
Randomized Controlled Trial
42%
MEDLINE
42%
Inclusion Criteria
28%
Corticosteroids
28%
Electronic Search
28%
Latin American
14%
Health Sciences
14%
Cochrane
14%
Science Literature
14%
Inflammatory Conditions
14%
Early Treatment
14%
Search Methods
14%
Meta-analysis
14%
Embase
14%
Selection Criteria
14%
Literature Database
14%
Alternative Therapy
14%
Medium Size
14%
Arterial Wall
14%
Effectiveness Study
14%
Large-sized
14%
World Health Organization
14%
Risk Assessment
14%
Blindness
14%
Disease-related
14%
Life-limiting Conditions
14%
Search Results
14%
Caribbean
14%
In-process
14%
Bias Analysis
14%
U.S. Food
14%
Adjunctive Use
14%
Risk of Bias
14%
Hemorrhagic Risk
14%
International Clinical Trials Registry Platform (ICTRP)
14%
High-dose Corticosteroids
14%
Issue 12
14%
ClinicalTrials.gov
14%
Concurrent Treatment
14%
Immune-mediated Inflammation
14%
Ischemic Complication
14%
Medicine and Dentistry
Acetylsalicylic Acid
100%
Giant-Cell Arteritis
100%
Low Drug Dose
57%
Randomized Controlled Trial
42%
Clinical Trial
14%
Serositis
14%
Clinician
14%
Adjuvant Therapy
14%
Meta-Analysis
14%
Drug Megadose
14%
Group Trial
14%
Diseases
14%
Side Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
100%
Giant Cell Arteritis
100%
Randomized Controlled Trial
42%
Inflammation
28%
Clinical Trial
14%
Group Trial
14%
Diseases
14%
Side Effect
14%
Nursing and Health Professions
Giant Cell Arteritis
100%
Low Drug Dose
57%
Inflammation
28%
Meta Analysis
14%
Drug Megadose
14%
Adjuvant Therapy
14%
Food and Drug Administration
14%
Diseases
14%
World Health Organization
14%
Efficacy
14%
Side Effect
14%
Biochemistry, Genetics and Molecular Biology
Foreign-Body Giant Cell
100%
Low Drug Dose
57%
Randomized Controlled Trial
42%
Clinical Trial
14%
Drug Megadose
14%
Group Trial
14%
Immunology and Microbiology
Giant Cell Arteritis
100%
Low Drug Dose
57%
Drug Megadose
14%
Artery
14%